drugset / Trial / NCT01341379

Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate

NCT01341379 ↗

NaSingle-groupOpen-labelTreatment

Summary

Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors of metabolism. The investigators propose to determine if short-term (3 day) treatment with N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients. The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators would consider more extensive long-term studies of the drug.

Timeline

Start
2010-12
Primary completion
2012-08
Completion
2012-08

Outcome

Outcome not reported

Stopped (Business): “Lack of funding”

Drugs

EvaluationDrugModalityDoseRoute
Subject N-carbamylglutamate Unknown 200 mg/kg Oral